Full
Outline
Metastatic castration-resistant prostate cancer (mCRPC) is an advanced stage of prostate cancer. It is resistant to first-line prostate cancer treatments and poses a significant threat to men's health. The prostate-specific membrane antigen (PSMA)-targeting radiopharmaceutical [177Lu]Lu-PSMA-617 has been approved by the FDA in 2022 to treat PSMA-positive patients with mCRPC, demonstrating significant clinical benefits on patients. In this work, we introduced a chelator, p-SCN-Bn-DOTA, instead of DOTA for radiolabeling and constructed the radioligand, PSMA-SCN, and systematically evaluated its diagnostic and therapeutic performance in prostate cancer. Both molecular docking and cellular competitive inhibition assays indicated that the introduction of p-SCN-Bn-DOTA enhanced the binding affinity of PSMA-SCN for the target protein PSMA compared to PSMA-617. For diagnosis, [68Ga]Ga-PSMA-SCN was used to evaluate the tumor imaging capability and in vivo metabolic profiling by microPET/CT. Quantitative analysis of microPET images shows higher tumor uptake of [68Ga]Ga-PSMA-SCN [(46.27 ± 0.45) and (31.15 ± 0.21)%ID·g-1] than that of [68Ga]Ga-PSMA-617 [(16.8 ± 0.98) and (13.38 ± 1.44)%ID·g-1] in LNCaP and RM-1 (PSMA+) tumor-bearing mouse models, respectively. [68Ga]Ga-PSMA-SCN also has faster clearance rates in non-targeted organs. The possible reason is that the introduction of p-SCN-Bn-DOTA improves the affinity of PSMA-SCN to the targeting protein and has no significant effect on pharmacokinetic metabolism. For therapeutics, [177Lu]Lu-PSMA-SCN was used in the treatment of tumor-bearing mice to assess its inhibitory effect on tumor growth, and the results demonstrated a favorable safety profile. These results confirm that PSMA-SCN has significant advantages in the theranostics of prostate cancer in comparison with PSMA-617. In conclusion, both theoretical analysis and biological evaluation of the PSMA-targeting molecule PSMA-SCN confirm its potential value for the diagnosis and treatment of prostate cancer. All experimental procedures involving animals were conducted in strict accordance with the ethical guidelines of the Institute of Materia Medica, Chinese Academy of Medical Sciences (ethics approval No. 00002217).
186
87
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
